Group 1 - The article discusses an ongoing investigation related to Johnson & Johnson, focusing on investors who have incurred losses [1] - The law firm Levi & Korsinsky is encouraging affected investors to reach out for assistance regarding the investigation [1] - The investigation may involve potential legal actions against Johnson & Johnson due to the financial losses experienced by investors [1]

Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Shareholders to Connect ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression, which is when trying at least two standard treatments does little to nothing to improve depression symptoms in a patient. Previously, Spravato was cleared in the U.S. to use together with an oral antidepress ...

Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms compared to placebo as early as 24 hours1  SPRAVATO® alone showed a rapid and superior improvement vs. placebo in the Montgomery-Asberg Depression Rating Scale (MADRS) total score, with numerical improvements across all 10 MADRS items seen at day 28 in a post-hoc analysis2Monotherapy data adds to well-established clin ...

Earnings and Estimates - The Zacks Consensus Estimate for JNJ Q4 sales and earnings is $22.5 billion and $2.01 per share, respectively [1] - The Zacks Consensus Estimate for JNJ's 2024 earnings has risen from $9.93 to $9.95 per share, while the 2025 estimate has declined from $10.54 to $10.50 per share over the past 60 days [2] - JNJ has exceeded earnings expectations in each of the trailing four quarters, with an average four-quarter earnings surprise of 4.15% [5][6] Stock Performance - JNJ stock has declined 9.5% in the past year, compared to a 5.4% decrease for the industry [1][17] - The stock has underperformed the sector and the S&P 500 [17] - JNJ shares currently trade at 13.95 forward earnings, lower than the industry's 15.29 and the stock's 5-year mean of 16.02 [19] Innovative Medicines Segment - Sales are expected to be driven by key products such as Darzalex, Tremfya, and Erleada [8] - The Zacks Consensus Estimate for Darzalex sales is $3.04 billion, while the model estimate is $3.06 billion [8] - The Zacks Consensus Estimate for Tremfya sales is $1.06 billion, while the model estimate is $1.09 billion [8] - The Zacks Consensus Estimate for Erleada sales is $793.8 million, while the model projects $805.0 million [9] - New drugs like Carvykti, Tecvayli, Talvey, and Spravato are likely to have contributed to top-line growth [9] MedTech Segment - Sales in the Asia Pacific region, specifically China, were hurt by the volume-based procurement program and anti-corruption campaign [13] - JNJ does not expect improvement in the Asia Pacific region in Q4 2024, but new product uptake and commercial execution are expected to boost growth in other markets [14] - The Zacks Consensus Estimate for the MedTech segment is $8.28 billion, while the model estimate is $8.23 billion [14] Acquisitions and Pipeline - JNJ completed acquisitions of Shockwave and V-Wave in MedTech, and Ambrx, Proteologix, and NM26 bispecific antibody in Innovative Medicine [23] - JNJ announced a definitive agreement to acquire Intra-Cellular Therapies for $14.6 billion, adding Caplyta and other CNS candidates to its pipeline [24] Challenges - Sales of key drug Stelara declined in Q3 2024 due to unfavorable patient mix and share loss in Europe [10] - Several biosimilar versions of Stelara are expected to be launched in the US in 2025 [11] - Imbruvica sales are likely to have declined due to rising competitive pressure in the US [12] - JNJ faces more than 62,000 lawsuits related to its talc-based products [25] Outlook - JNJ's outlook for 2025 looks positive, with growth expected in the Innovative Medicine segment driven by key products and new drugs [26] - In MedTech, operational sales growth is expected to be at the upper end of the 5-7% long-term guided range, driven by new product launches and acquisitions [26]

Johnson & Johnson (JNJ) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates ...

Earnings and Analyst Expectations - Johnson & Johnson (JNJ) is set to report earnings with analysts expecting revenue and profit growth compared to the same period last year [2] - Revenue is expected to rise to $22.51 billion from $21.4 billion, and net income to $4.4 billion from $4.05 billion in Q4 2023 [3] - Analysts are cautiously optimistic, with 6 out of 12 analysts giving a "buy" rating and 6 giving a "hold" rating, with an average price target of $175 implying 19% upside from Friday's close [2] Stock Performance - Johnson & Johnson shares trended lower from mid-October through the end of 2024, ending the year down nearly 8% [3] - The stock has gained close to 2% in January, closing at $147.03 as of Friday [3] Challenges and Risks - The company faces unresolved class action lawsuits related to its talc powder, with hearings scheduled early this year to determine the fate of a subsidiary's bankruptcy plan and a multi-billion dollar settlement [4] - An expiring patent for one of its popular drugs is expected to bring competition [4] - The company's AAA credit rating is at risk due to recent acquisitions, including the $14.6 billion deal to acquire Intra-Cellular Therapies (ITCI), which is expected to be financed with a combination of cash and debt [5] Strategic Moves - Johnson & Johnson made several acquisitions in 2024 and started 2025 with the acquisition of Intra-Cellular Therapies (ITCI) for $14.6 billion, expected to close this year [5]

Shareholders That Lost Money on Johnson & Johnson (JNJ) Should Contact Levi & Korsinsky About Securities Fraud Investigation - JNJ ...

Johnson & Johnson (JNJ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation ...

Shareholder Rights Advocates at Levi & Korsinsky Investigate Johnson & Johnson (JNJ) Regarding Possible Securities Fraud Violations ...